Synchron Secures $200M to Expand Stentrode BCI Commercialisation
US-based neurotechnology company Synchron has raised $200 million in a Series D funding round to accelerate the global rollout of its Stentrode brain-computer interface (BCI) platform and develop next-generation neural interfaces.
Investment and Participants
The funding round was led by Double Point Ventures, with participation from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI. New investors included the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Strategic Goals
Synchron plans to use the capital to speed up key clinical trials and expand its multidisciplinary team. The company aims to advance the Stentrode platform toward wider clinical and commercial adoption.
CEO Statement
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis,” said Synchron founder and CEO Tom Oxley. “This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a next-generation, transcatheter high-channel whole-brain interface.”
About Synchron
Synchron’s Stentrode technology represents a major step forward in neural engineering, offering a minimally invasive solution for connecting the human brain to digital systems without the need for open brain surgery.
Author’s Summary: Synchron’s $200M Series D funding positions it to bring its innovative non-surgical brain-computer interface to market faster and expand clinical research efforts worldwide.